Observational studyMedicine2026
Does previous COVID-19 severity affect propofol sedation safety during ERCP?: A prospective observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) requires deep sedation, typically with propofol, because of its rapid onset and recovery time. However, propofol can cause respiratory and hemodynamic instability. Because Coronavirus Disease 2019 (COVID-19) can induce long-term pulmonary and cardiovascular dysfunction, previous COVID-19 infection may influence sedation safety. This study aimed to evaluate the effects of COVID-19 infection severity on respiratory, hemodynamic, and recovery parameters during ERCP with propofol sedation. This prospective observational study included adult patients who underwent ERCP using propofol. Patients were divided into those without a COVID-19 history (COVID-) and those with a polymerase chain reaction-confirmed prior infection (COVID+), stratified by severity (mild, moderate, or severe). The primary outcome was hypoxemia (peripheral oxygen saturation < 90%). Secondary outcomes included apnea, airway interventions, hemodynamic instability, vasopressor use, recovery time, and patient complications. Multivariate logistic regression was used to adjust for confounders, including the American Society of Anesthesiologists physical status. A total of 326 patients were analyzed (163 COVID- and 163 COVID+ patients). Patients in the COVID+ group were classified as mild (n = 105), moderate (n = 46), or severe (n = 12). No significant differences were observed between the COVID and mild COVID+ groups in terms of hypoxemia or complications. Conversely, patients with a history of moderate or severe COVID-19 infection exhibited significantly higher rates of hypoxemia, apnea, airway interventions, vasopressor use, prolonged recovery, and postoperative oxygen requirements. Multivariate analysis identified a history of moderate-to-severe COVID-19 as an independent risk factor for hypoxemia. In conclusion, patients with a history of moderate or severe COVID-19 infection may be at increased risk for respiratory complications during propofol sedation for ERCP. Preoperative risk stratification should prioritize the severity of previous COVID-19 infection rather than just the history of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.